Indeed, innovation and technologies (injectables in pre-filled syringes, preparations for topical use in BoV [Bag-on-Valve] and soft capsules) have been the subject of a close analysis by Alessandro Spada, in IBSA’s ultra-modern production plant. The President and his collaborators were accompanied by Mr. Roberto Maglio – Engineer and Sr. Site Manager – along a path where they were able to see first-hand how innovation, research and development merge to give life to products with a high added value, and how all this is made possible by the commitment and professional skills of IBSA’s collaborators.
“In 2021, IBSA Farmaceutici was the Italian pharma company that invested most in research and development, two strategic levers to reinforce growth. It is therefore a virtuous example of how innovation represents an opportunity to make the territory and our industrial system more competitive on a global level”, read the statement released by the President of Assolombarda at the end of the visit.
Indeed, by expanding its workforce and confirming its investment plan of € 15 million, IBSA Farmaceutici consolidates its commitment to the economic recovery, developing the new Lodi headquarters from a completely green perspective, with sustainable solutions and renewable energy sources, able to represent a great place to work for all collaborators, together with the Company’s strong commitment to Corporate Social Responsibility projects.
“Welcoming the President of Assolombarda, Alessandro Spada, to our headquarters in Lodi was a source of pride for all of us”, declared Luca Crippa, CEO & Managing Director of IBSA Farmaceutici. “Our company works every day to enhance Personal Care, while positioning itself as a strategic player in the area of innovation”.
